|
Real-time Estimate
Cboe BZX
12:22:43 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 98.16 USD | +0.57% |
|
+4.19% | +23.83% |
| 08-25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology | MT |
| 08-25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology, CNBC Reports | MT |
| Market Cap | 125B 0 0 0 0 0 0 0 0 0 0 0 0 | P/E 2026 * |
14.4x | P/E 2027 * | 13.7x |
|---|---|---|---|---|---|
| Enterprise Value | 177B 0 0 0 0 0 0 0 0 0 0 0 0 | EV / Sales 2026 * |
0.42x | EV / Sales 2027 * | 0.41x |
| Free-Float |
71.17% | Yield 2026 * |
2.73% | Yield 2027 * | 2.81% |
Last Transcript : CVS Health Corporation
| 1 day | +0.56% | ||
| 1 week | +4.19% | ||
| Current month | +4.64% | ||
| 1 month | -6.74% | ||
| 3 months | +9.80% | ||
| 6 months | +20.34% | ||
| Current year | +23.83% |
| 1 week | 92.85 |  | 98.5 |
| 1 month | 92.35 | | 105.69 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 5/31/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 5/21/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.56% | +4.19% | +32.64% | +49.78% | 125B | |
| -0.74% | -4.04% | +0.93% | +49.46% | 89.54B | |
| -2.53% | +0.02% | -1.83% | +55.76% | 29.24B | |
| +1.85% | -1.97% | +34.40% | +88.75% | 26.07B | |
| -1.79% | -4.11% | -5.49% | -5.02% | 21.91B | |
| -1.92% | -4.87% | +40.72% | +240.33% | 21.41B | |
| +3.50% | +4.90% | -4.93% | +27.25% | 15.11B | |
| -0.46% | -2.48% | -5.61% | -11.71% | 12.15B | |
| +1.96% | -0.56% | +30.74% | +85.25% | 11.23B | |
| -1.29% | -2.07% | -15.74% | +72.79% | 10.33B | |
| Average | -0.07% | -1.10% | +10.58% | +65.26% | 36.18B | |
| Weighted average by Cap. | -0.12% | +0.17% | +16.01% | +59.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 0 0 0 0 0 0 0 0 0 0 0 0 | 430B 0 0 0 0 0 0 0 0 0 0 0 0 |
| Net income | 8.79B 0 0 0 0 0 0 0 0 0 0 0 0 | 9.11B 0 0 0 0 0 0 0 0 0 0 0 0 |
| Net Debt | 51.92B 0 0 0 0 0 0 0 0 0 0 0 0 | 49.15B 0 0 0 0 0 0 0 0 0 0 0 0 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-02 | US$98.23 | +0.65% | 1,707,894 |
| 26-09-01 | US$97.60 | +3.93% | 8,614,487 |
| 26-08-31 | US$93.91 | +0.91% | 10,676,760 |
| 26-08-28 | US$93.06 | +0.15% | 3,994,223 |
| 26-08-27 | US$92.92 | -1.48% | 4,330,313 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
